- Home
- YHGJ vs APLM Comparison
YHGJ vs APLM Comparison
Compare YHGJ & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHGJ
- APLM
- Stock Information
- Founded
- YHGJ 1975
- APLM 2016
- Country
- YHGJ United States
- APLM United States
- Employees
- YHGJ N/A
- APLM N/A
- Industry
- YHGJ Specialty Chemicals
- APLM Blank Checks
- Sector
- YHGJ Industrials
- APLM Finance
- Exchange
- YHGJ Nasdaq
- APLM Nasdaq
- Market Cap
- YHGJ 14.0M
- APLM 12.3M
- IPO Year
- YHGJ 1997
- APLM N/A
- Fundamental
- Price
- YHGJ $0.60
- APLM $9.15
- Analyst Decision
- YHGJ
- APLM Strong Buy
- Analyst Count
- YHGJ 0
- APLM 2
- Target Price
- YHGJ N/A
- APLM $425.00
- AVG Volume (30 Days)
- YHGJ 231.9K
- APLM 16.7K
- Earning Date
- YHGJ 02-19-2025
- APLM 02-15-2025
- Dividend Yield
- YHGJ N/A
- APLM N/A
- EPS Growth
- YHGJ N/A
- APLM N/A
- EPS
- YHGJ N/A
- APLM N/A
- Revenue
- YHGJ $18,559,000.00
- APLM $2,101,000.00
- Revenue This Year
- YHGJ N/A
- APLM N/A
- Revenue Next Year
- YHGJ N/A
- APLM N/A
- P/E Ratio
- YHGJ N/A
- APLM N/A
- Revenue Growth
- YHGJ 11.78
- APLM 70.54
- 52 Week Low
- YHGJ $0.43
- APLM $6.50
- 52 Week High
- YHGJ $1.85
- APLM $80.50
- Technical
- Relative Strength Index (RSI)
- YHGJ 51.40
- APLM 42.70
- Support Level
- YHGJ $0.52
- APLM $8.23
- Resistance Level
- YHGJ $0.76
- APLM $8.94
- Average True Range (ATR)
- YHGJ 0.11
- APLM 0.55
- MACD
- YHGJ 0.01
- APLM -0.12
- Stochastic Oscillator
- YHGJ 14.40
- APLM 20.27
About YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.